Seongho Kim
Office Address
87 East Canfield Street
Detroit, MI 48201
Department
Oncology
Laboratory Web Site
https://www.ncbi.nlm.nih.gov/myncbi/seong%20ho.kim.1/bibliography/public/
Research Interests
Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis; High-throughput data analysis; Disease progressive modeling; Metabolomics.
Research Description
Dr. Kim's research interests lie in the data analysis and the methodology development for biological and clinical cancer data. He has participated in various research projects, including pattern recognitions, decision support systems, comparative genomics, proteomics, metabolomics, pharmacokinetics/pharmacodynamics, biomarker discovery, high-dimensional data analysis, pathway analysis, clinical trial design and cancer screening.
Recent Publications
Manning M, Jiang Y, Wang R, Liu L, Rode S, Bonahoom M, Kim S, Yang ZQ. Pan-cancer analysis of RNA methyltransferases identifies FTSJ3 as a potential regulator of breast cancer progression. RNA Biol. 2020;17:474-86.
Conner KL, Shaik AN, Ekinci E, Kim S, Ruterbusch JJ, Cote ML, Patrick SM. HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer. DNA Repair (Amst). 2020;87:102802.
Wasinski B, Sohail A, Bonfil RD, Kim S, Saliganan A, Polin L, Bouhamdan M, Kim HC, Prunotto M, Fridman R. Discoidin Domain Receptors, DDR1b and DDR2, Promote Tumour Growth within Collagen but DDR1b Suppresses Experimental Lung Metastasis in HT1080 Xenografts. Sci Rep. 2020;10:2309.
Warner RB, Najy AJ, Jung YS, Fridman R, Kim S, Kim HC. Establishment of Structure-Function Relationship of Tissue Inhibitor of Metalloproteinase-1 for Its Interaction with CD63: Implication for Cancer Therapy. Sci Rep. 2020;10:2099.
Morreale MK, Moore TF, Kim S, Uphold HS, Mabunda LM, Harper FWK. Preferences for notification of imaging results in patients with metastatic cancer. Patient Educ Couns. 2020;103:392-7.
Shah H, Kim S, Singh P, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Deol A. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol. 2020;95:198-204.
Pardy L, Rosati R, Soave C, Huang Y, Kim S, Ratnam M. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer. Prostate. 2020;80:198-208.
Hamel LM, Dougherty DW, Albrecht TL, Wojda M, Jordan A, Moore TF, Senft N, Carducci M, Heath EI, Manning MA, Penner LA, Kim S, Eggly S. Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial. JCO Oncol Pract. 2020;16:e124-e131.
Dekhne AS, Ning C, Nayeen MJ, Shah K, Kalpage H, Frühauf J, Wallace-Povirk A, O'Connor C, Hou Z, Kim S, Hüttemann M, Gangjee A, Matherly LH. Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism. Mol Pharmacol. 2020;97:9-22.
Herroon MK, Diedrich JD, Rajagurubandara E, Martin C, Maddipati KR, Kim S, Heath EI, Granneman J, Podgorski I. Prostate Tumor Cell-Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms. Mol Cancer Res. 2019;17:2508-21.
Selected publications
Rosati R, Polin LA, Ducker C, Li J, Bao X, Selvakumar D, Kim S, Xhabija B, Larsen M, McFall T, Huang Y, Kidder BL, Fribley A, Saxton J, Kakuta H, Shaw PE, Ratnam M. Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. Clin Cancer Res. 2018 Sep 5. pii: clincanres.0982.2018. doi: 10.1158/1078-0432.CCR-18-0982. [Epub ahead of print].
Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM. Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients. Clin Cancer Res. 2018;24:3820-28.
Bao X, Wu J, Kim S, LoRusso P, Li J. Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients. J Clin Pharmacol. 2018 Jul 27. doi: 10.1002/jcph.1275. [Epub ahead of print]
Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P. Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2018 Jul 23. doi: 10.1038/s41409-018-0270-x. [Epub ahead of print].
Prodhan MAI, Yin X, Kim S, McClain C, Zhang X. Surface fitting for calculating the second dimension retention index in comprehensive two-dimensional gas chromatography mass spectrometry. J Chromatogr A. 2018;1539:62-70.
McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem. 2018;293:1163-77.
Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, Sparreboom A, Sanai N. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach. Clin Cancer Res. 2017;23:7454-66.
Eggly S, Hamel LM, Heath E, Manning MA, Albrecht TL, Barton E, Wojda M, Foster T, Carducci M, Lansey D, Wang T, Abdallah R, Abrahamian N, Kim S, Senft N, Penner LA. Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials. BMC Cancer. 2017;17:807.
Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. Bone Marrow Transplant. 2017;52:1530-36.
Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, Dickow B, Heath E, Fontana J, Vaishampayan U. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:82.
Education/Training
Post-doctoral Fellow in Biostatistics (2008): Indiana University School of Medicine, Indianapolis, IN
Post-doctoral Fellow in Bioinformatics (2006): Georgia Institute of Technology, Atlanta, GA
PhD in Applied Statistics (2005): KAIST, South Korea
Courses Taught
CB7600 Applied Cancer Biostatistics (Course Director)
CB7700 Journal Club
CB7800 Rigor & Reproducibility